These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 870771)

  • 1. Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations.
    Engel AG; Lambert EH; Howard FM
    Mayo Clin Proc; 1977 May; 52(5):267-80. PubMed ID: 870771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Passively transferred experimental autoimmune myasthenia gravis. Sequential and quantitative study of the motor end-plate fine structure and ultrastructural localization of immune complexes (IgG and C3), and of the acetylcholine receptor.
    Engel AG; Sakakibara H; Sahashi K; Lindstrom JM; Lambert EH; Lennon VA
    Neurology; 1979 Feb; 29(2):179-88. PubMed ID: 571062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultrastructural localization of immune complexes (IgG and C3) at the end-plate in experimental autoimmune myasthenia gravis.
    Sahashi K; Engel AG; Linstrom JM; Lambert EH; Lennon VA
    J Neuropathol Exp Neurol; 1978; 37(2):212-23. PubMed ID: 147324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The immunopathology of acquired myasthenia gravis.
    Engel AG; Sahashi K; Fumagalli G
    Ann N Y Acad Sci; 1981; 377():158-74. PubMed ID: 6951470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-function correlations in myasthenia gravis and a new myasthenic syndrome.
    Engel AG; Lambert EH
    Electroencephalogr Clin Neurophysiol Suppl; 1978; (34):469-77. PubMed ID: 220007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Study of antibodies to motor end-plate in ocular myasthenia gravis].
    Kinoshita I; Tsujihata M; Motomura M; Yoshimura T; Nagataki S
    Rinsho Shinkeigaku; 1991 May; 31(5):500-4. PubMed ID: 1934762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction.
    Gomez AM; Van Den Broeck J; Vrolix K; Janssen SP; Lemmens MA; Van Der Esch E; Duimel H; Frederik P; Molenaar PC; Martínez-Martínez P; De Baets MH; Losen M
    Autoimmunity; 2010 Aug; 43(5-6):353-70. PubMed ID: 20380584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic significance of IgG, C3, and C9 at the limb muscle motor end-plate in minimal myasthenia gravis.
    Tsujihata M; Yoshimura T; Satoh A; Kinoshita I; Matsuo H; Mori M; Nagataki S
    Neurology; 1989 Oct; 39(10):1359-63. PubMed ID: 2797459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The immunopathological basis of acetylcholine receptor deficiency in myasthenia gravis.
    Engel AG
    Prog Brain Res; 1979; 49():423-34. PubMed ID: 515440
    [No Abstract]   [Full Text] [Related]  

  • 10. [Clinical significance of immune complexes at the motor endplate in myasthenia gravis].
    Tsujihata M; Yoshimura T; Satoh A; Hazama R; Mori M
    Rinsho Shinkeigaku; 1983 Sep; 23(9):735-43. PubMed ID: 6673871
    [No Abstract]   [Full Text] [Related]  

  • 11. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis.
    Shiraishi H; Motomura M; Yoshimura T; Fukudome T; Fukuda T; Nakao Y; Tsujihata M; Vincent A; Eguchi K
    Ann Neurol; 2005 Feb; 57(2):289-93. PubMed ID: 15668981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ultrastructural aspects of acetylcholine receptor turnover at the normal end-plate and in autoimmune myasthenia gravis.
    Fumagalli G; Engel AG; Lindstrom J
    J Neuropathol Exp Neurol; 1982 Nov; 41(6):567-79. PubMed ID: 6982313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myasthenogenicity of a human acetylcholine receptor alpha-subunit peptide: morphology and immunology.
    Matsuo H; Tsujihata M; Satoh A; Takeo G; Yoshimura T; Nagataki S
    Muscle Nerve; 1992 Mar; 15(3):282-7. PubMed ID: 1372965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effector mechanisms in myasthenia gravis: end-plate function after passive transfer of IgG, Fab, and F(ab')2 hybrid molecules.
    Sterz R; Hohlfeld R; Rajki K; Kaul M; Heininger K; Peper K; Toyka KV
    Muscle Nerve; 1986 May; 9(4):306-12. PubMed ID: 2423869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Myasthenia gravis. Prototype of an anti-receptor autoaggression disease (author's transl)].
    Hohlfeld R; Wekerle H
    MMW Munch Med Wochenschr; 1981 Jul; 123(31):1207-11. PubMed ID: 6790965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice.
    Klooster R; Plomp JJ; Huijbers MG; Niks EH; Straasheijm KR; Detmers FJ; Hermans PW; Sleijpen K; Verrips A; Losen M; Martinez-Martinez P; De Baets MH; van der Maarel SM; Verschuuren JJ
    Brain; 2012 Apr; 135(Pt 4):1081-101. PubMed ID: 22396395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myasthenia gravis without acetylcholine-receptor antibody: a distinct disease entity.
    Mossman S; Vincent A; Newsom-Davis J
    Lancet; 1986 Jan; 1(8473):116-9. PubMed ID: 2417076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The motor end plate in myasthenia gravis and in experimental autoimmune myasthenia gravis. A quantitative ultrastructural study.
    Engel AG; Tsujihata M; Lindstrom JM; Lennon VA
    Ann N Y Acad Sci; 1976; 274():60-79. PubMed ID: 1066997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
    Cole RN; Reddel SW; Gervásio OL; Phillips WD
    Ann Neurol; 2008 Jun; 63(6):782-9. PubMed ID: 18384168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Properties of end-plate channels in rats immunized against acetylcholine receptors.
    Alemà S; Cull-Candy SG; Miledi R; Trautmann A
    J Physiol; 1981 Feb; 311():251-66. PubMed ID: 6267252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.